Kentrican is a private company which was established in 2021. The Management is planning to establish a production facility for pharmaceutical cannabis, recognizing a significant opportunity in this sector. This decision is influenced by the increasingly lenient legal and legislative frameworks in several EU countries.
The primary products of Kentrican will be dried flowers and cannabis oil, both anticipated to have a high THC concentration recognized for its psychotropic effects. According to the Management, the THC levels in these products are expected to range from 10% to 33%.
Stage The Company has not yet commenced operations and is currently in the pre-operational phase, with the intention to specialize in the cultivation and the production of dried cannabis flower and cannabis oil for medical purposes